InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,481.85
(
0.32%
)
US TECH 100
19,093.20
(
-0.59%
)
Dow Jones
39,412.03
(
0.67%
)
Brent Oil
84.72
(
0.83%
)
Bitcoin
61,601.18
(
-2.46%
)
Post# of 252314
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

jq1234

Send PM Follow Ignore
Followers 68
Posts 4505
Boards Moderated 0
Alias Born 12/13/2009

jq1234

Re: None

Thursday, 01/27/2011 4:58:25 PM

Thursday, January 27, 2011 4:58:25 PM

Post# of 252314
Sanofi-aventis Reports Top-line Results
from Phase III Study with BSI-201 in Metastatic
Triple-Negative Breast Cancer

Paris, France - January 27, 2011 - Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) and its subsidiary,
BiPar Sciences, today announced that a randomized Phase III trial evaluating BSI-201 (iniparib*) in patients
with metastatic triple-negative breast cancer (mTNBC) did not meet the pre-specified criteria for significance
for co-primary endpoints of overall survival and progression-free survival.

http://en.sanofi-aventis.com/binaries/20110127_BSI_en_tcm28-30168.pdf
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up